Skip to content

Study · Other design · 2018

5 results

Intranasal oxytocin decreases cross-frequency coupling of neural oscillations at rest.

Rutherford HJV, Guo XM, Wu J, Graber KM, Hayes NJ, Pelphrey KA, Mayes LC

International journal of psychophysiology : official journal of the International Organization of Psychophysiology28 Sept 2017Cited by 11 (Europe PMC)

PMID28965930 (opens in a new tab)DOI10.1016/j.ijpsycho.2017.09.017 (opens in a new tab)PepBankPUB-28965930
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanOther designMechanism

    Intranasal oxytocin did not change resting-state neural oscillations compared with placebo.

    In plain wordsIntranasal oxytocin did not change resting brain wave activity compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeResting neural oscillation power (delta, theta, alpha, beta)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    While neural oscillations were unaffected by oxytocin relative to placebo administration; oxytocin decreased delta-beta, delta-alpha, theta-alpha, and theta-beta coupling.
    1 context sentence
    Summary · context
    In a double-blind placebo controlled design using electroencephalography, the effects of intranasal oxytocin on neural oscillations (delta, theta, alpha, beta) and their coupling during the resting state were examined.
  2. 02HumanOther designMechanism

    Intranasal oxytocin decreased resting delta-beta cross-frequency coupling compared with placebo.

    In plain wordsIntranasal oxytocin lowered the coupling between two resting brain wave bands compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseDelta-beta cross-frequency coupling
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    While neural oscillations were unaffected by oxytocin relative to placebo administration; oxytocin decreased delta-beta, delta-alpha, theta-alpha, and theta-beta coupling.
    1 context sentence
    Summary · context
    In a double-blind placebo controlled design using electroencephalography, the effects of intranasal oxytocin on neural oscillations (delta, theta, alpha, beta) and their coupling during the resting state were examined.
  3. 03HumanOther designMechanism

    Intranasal oxytocin decreased resting delta-alpha cross-frequency coupling compared with placebo.

    In plain wordsIntranasal oxytocin lowered the coupling between two resting brain wave bands compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseDelta-alpha cross-frequency coupling
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    While neural oscillations were unaffected by oxytocin relative to placebo administration; oxytocin decreased delta-beta, delta-alpha, theta-alpha, and theta-beta coupling.
    1 context sentence
    Summary · context
    In a double-blind placebo controlled design using electroencephalography, the effects of intranasal oxytocin on neural oscillations (delta, theta, alpha, beta) and their coupling during the resting state were examined.
  4. 04HumanOther designMechanism

    Intranasal oxytocin decreased resting theta-alpha cross-frequency coupling compared with placebo.

    In plain wordsIntranasal oxytocin lowered the coupling between two resting brain wave bands compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseTheta-alpha cross-frequency coupling
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    While neural oscillations were unaffected by oxytocin relative to placebo administration; oxytocin decreased delta-beta, delta-alpha, theta-alpha, and theta-beta coupling.
    1 context sentence
    Summary · context
    In a double-blind placebo controlled design using electroencephalography, the effects of intranasal oxytocin on neural oscillations (delta, theta, alpha, beta) and their coupling during the resting state were examined.
  5. 05HumanOther designMechanism

    Intranasal oxytocin decreased resting theta-beta cross-frequency coupling compared with placebo.

    In plain wordsIntranasal oxytocin lowered the coupling between two resting brain wave bands compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseTheta-beta cross-frequency coupling
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    While neural oscillations were unaffected by oxytocin relative to placebo administration; oxytocin decreased delta-beta, delta-alpha, theta-alpha, and theta-beta coupling.
    1 context sentence
    Summary · context
    In a double-blind placebo controlled design using electroencephalography, the effects of intranasal oxytocin on neural oscillations (delta, theta, alpha, beta) and their coupling during the resting state were examined.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.